MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
(NASDAQ: INKT) Delayed: 12.05 +0.34 (2.90%)
Previous Close $11.71    52 Week High $ 
Open $12.00    52 Week Low $ 
Day High $12.08    P/E N/A 
Day Low $11.70    EPS $ 
Volume 18,909